Prediction of Response to Androgen Deprivation Therapy and Castration Resistance in Primary Metastatic Prostate Cancer

Publisher： Karger

E-ISSN： 1423-0399|88|1|25-33

ISSN： 0042-1138

Source： Urologia Internationalis, Vol.88, Iss.1, 2011-12, pp. : 25-33

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The predictive value of ERG protein expression for development of castration‐resistant prostate cancer in hormone‐naïve advanced prostate cancer treated with primary androgen deprivation therapy

By  

THE PROSTATE, Vol. 75, Iss. 14, 2015-10 ,pp. : 1499-1509

John Wiley & Sons Inc

Access to resources Recommend Favorite

The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancer

By  

THE PROSTATE, Vol. 75, Iss. 9, 2015-06 ,pp. : 897-906

John Wiley & Sons Inc

Access to resources Recommend Favorite

Early Docetaxel and Androgen Deprivation in the Treatment of Metastatic, Hormone-sensitive Prostate Cancer

By  

Reviews on Recent Clinical Trials, Vol. 11, Iss. 4, 2016-10 ,pp. : 317-323

Bentham Science Publishers

Access to resources Recommend Favorite

Mediators of the resistance and aerobic exercise intervention effect on physical and general health in men undergoing androgen deprivation therapy for prostate cancer

By  

CANCER, Vol. 120, Iss. 2, 2014-01 ,pp. : 294-301

John Wiley & Sons Inc

Access to resources Recommend Favorite

Effect of androgen deprivation therapy on the contractile properties of type I and type II skeletal muscle fibres in men with non‐metastatic prostate cancer

By  

CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (ELECTRONIC), Vol. 45, Iss. 2, 2018-02 ,pp. : 146-154

John Wiley & Sons Inc

Access to resources Recommend Favorite